Spironolactone in diastolic dysfunction

This randomized trial found in patients with Stage 2-3 diastolic dysfunction, spironolactone improved diastolic dysfunction, but had no effect on symptoms, exercise capacity, or quality of life; and it was associated higher potassium levels and lower GFR. The current weight of the evidence does not support the use of spironolactone in diastolic dysfunction (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment